Thaindian News

Mar 12 (Pen Men at Work): American watchdogs have declared that they have not discovered any association between oral bisphosphonate osteoporosis medicines such as Merck & Co Inc.’s Fosamax and some thigh bone fissures.

The U.S. Food and Drug Administration (FDA) released its proclamation on Wednesday subsequent to the circulation of case reports of uncharacteristic subtrochanteric femur fractures — or fractures in the bone just beneath the hip joint — in ladies with osteoporosis consuming oral bisphosphonates. Bisphosphonates are a category of drugs, which are focused on thwarting bone breakages and counterbalancing bone loss connected with menopause. They include Fosamax, Roche Holding AG’s Boniva, Novartis’ Reclast and Warner Chilcott’s Actonel.

In June 2008, the FDA demanded data from all bisphosphonate drug manufacturers connected to these sorts of breakage. The organization held that an appraisal of the facts did not illustrate an augmented menace for women utilizing the medications. The FDA mentioned that, although its examination of the data did not explain a comprehensible relationship between bisphosphonates and nonconforming subtrochanteric femur fractures, the agency is running closely with outside specialists to achieve more insightfulness into the matter.

Bisphosphonates, which have existed in the marketplace for more or less a decade, had been associated with security concerns some time ago, including jeopardizing the heart.

In January, a Manhattan federal judge refused to dismiss a lawsuit alleging that Fosamax caused damage to the jaw of a female for the period of nearly eight years she made use of the pill. Merck has had to deal with a wide range of lawsuits involving just about 900 cases by patients, who have alleged that Fosamax led to the osteonecrosis of the jaw, or demise of the jawbone tissue.

Merck spokesperson, Ron Rogers, uttered in a declaration that, in scientific studies, Fosamax has not been allied with enlarged fracture threat at any skeletal location. Rogers observed that little energy femoral shaft and subtrochanteric fissures have been reported in the health literature as taking place in non-bisphosphonate consumers. He also stated that Merck is, at this time, performing studies to additionally explore the question of low energy femoral shaft and subtrochanteric breakages.

The FDA counseled that the patients keep swallowing their pills unless told not to do so by their medical doctor. It also suggested that healthcare professionals be conscious of a potential hazard of unusual subtrochanteric femur fractures in patients gobbling oral bisphosphonates.